MTM Laboratories AG to Present at Biotechnology Industry Organization (BIO)-Europe 2009 in Vienna/Austria
Published: Oct 27, 2009
The biomarker that mtm uses in its screening and diagnostic products is the cyclin-dependent kinase inhibitor p16INK4a, the over-expression of which has been shown to be a highly specific marker of the onset of cervical cancer. It is crucial to a positive prognosis that cervical cancer is identified and treated as early as possible and p16INK4a as a biomarker makes such early accurate diagnoses possible.
BIO-Europe brings together international decision-makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop participation, and private, pre-scheduled one-to-one meetings. Investment and collaboration opportunities developed in prior BIO- Europe conferences have produced many highly successful business partnerships.
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with the headquarter in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com.